Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia

Sleep

Volumn 30, Issue 11, 2007, Pages 1555-1561

  Roth, Thomas ^a   Rogowski, Roberta ^b   Hull, Steven ^c   Schwartz, Howard ^d   Koshorek, Gail ^a   Corser, Bruce ^e   Seiden, David ^f   Lankford, Alan ^g  

^a HENRY FORD HOSPITAL   (United States)

^b Somaxon Pharmaceuticals Inc   (United States)

^c Vince and Associates Clinical Research   (United States)

^d MIAMI RESEARCH ASSOCIATES   (United States)

^e Community Research Management Associates ^*  (United States)

^f Broward Research Group   (United States)

^g Sleep Disorders Center of Georgia   (United States)

Author keywords

Chronic insomnia; Doxepin; Sleep maintenance insomnia; Terminal insomnia; Total sleep time; Wake time after sleep onset; Wake time during sleep

Indexed keywords

DOXEPIN; PLACEBO;

ADULT; ANTICHOLINERGIC EFFECT; ANXIETY; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HANGOVER; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP TIME; SOMNOLENCE;

EID: 34548249175     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/30.11.1555     Document Type: Article

References (25)

1. Breslau N, Roth T, Rosenthal L, et al. Sleep disturbance and psychiatric disorders: A longitudinal epidemiological study of young adults. Biol Psychiatry 2004;39:411-8.
2. Ohayon MM. Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders. J Psychiatr Res 1997;31:333-46.
3. Lichstein KL, Durrence HH, Taylor DJ, et al. Epidemiology of sleep: age, gender, and ethnicity. Mahwah, NJ: Erlbaum; 2004.
4. Buysse D, Reynolds CF III, Kupfer DJ, et al. Effects of diagnosis on treatment recommendations in chronic insomnia-a report from the APA/NIMH DSM-IV field trial. Sleep 1997;20:542-52.
5. Katz DA, McHorney CA. Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med 1998;158:1099-107.
6. Glass J, Lanctot KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: A meta-analysis of risks and benefits. BMJ 2005;331:1169-73.
7. Koski, Luukinen H, Laippala P, et al. Risk factors for major injurious falls among the home-dwelling elderly by functional abilities. Gerontology 1998;44:232-8.
8. Vermeeren A. Residual effects of hypnotics. CNS Drugs 2004;18:297-328.
9. Hajak G, Muller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 2003;98:1371-8.
10. National Institutes of Health. NIH State-of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. 2005; final statement available at: http://consensus.nih.gov/2005/ 2005InsomniaSOS026html.htm.
11. Roth T, Zorick F, Wittig R, et al. The effects of doxepin HCl on sleep and depression. J Clin Psychiatry 1982;43:366-8.
12. Hajak G, Rodenbeck A, Adler L, et al. Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Pharmacopsychiatry, 1996;29:187-92.
13. Rodenbeck A, Cohrs S, Jordan W, et al. The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. Psychopharmacology 2003;170:423-8.
14. Hajak G, Rodenbeck A, Voderholzer U, et al. Doxepin in the treatment of primary insomnia: A placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry, 2001;62:453-63.
15. Leonard B, Richelson E. Synaptic effects of antidepressants, in Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practise (Buckley PF and Waddington JL eds). 2000;67-84, Butterworth-Heinemann, Boston, MA.
16. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997;283:1305-22.
17. Rosenberg R. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry 2006;18:49-56.
18. Hill SJ, Ganellin C, Timmerman H, et al. International union of pharmacology. XIII. Classification of histamine receptors. Pharmacol Rev, 1997;49:253-78.
19. John J, Wu M, Boehmer L, Siegel J. Cataplexy-active neurons in the hypothalamus: Implications for the role of histamine in sleep and waking behavior. Neuron 2004;42:619-34.
20. Ramesh V, Thakkar M, Strecker R, et al. Wakefulness-inducing effects of histamine in the basal forebrain of freely moving rats. Behavioural Brain Res 2004;152:271-8.
21. Inoue I, Yanai K, Kiamura D, et al. Impaired locomotor activity and exploratory behavior in mice lacking histamin H1 receptors. Proceedings of the National Academy of Sciences of United States of America 1996;93:13316-20.
22. Monti J, Pellejero T, Jantos H. Effects of H1- and H2-histamine receptor agonists and antagonists on sleep and wakefulness in the rat. J Neural Transm 1986;66:1-11.
23. Tashiro M, Mochizuki H, Iwabuchi K, et al. Roles of histamine in regulation of arousal and cognition: Functional neuroimaging of histamine H1 receptors in human brain. Life Sci 2002;72:409-14.
24. Yanai K, Son LZ, Endou M, et al. Behavioural characterization and amounts of brain monoamines and their metabolites in mice lacking histamine H1 receptors. Neuroscience 1998;87:479-87.
25. Edgar D, Dement W, Fuller C. Effect of SCN lesions on sleep in squirrel monkeys: Evidence for opponent processes in sleep-wake regulation. J Neurosci 1993;13:1065-79.